Pharvaris price target raised to $55 from $46 at JMP Securities

JMP Securities analyst Jonathan Wolleben raised the firm’s price target on Pharvaris (PHVS) to $55 from $46 and keeps an Outperform rating on the shares. Pharvaris is the only company with an oral candidate for hereditary angioedema prophylaxis and on demand treatment, the analyst tells investors. Additionally, the company’s extended release version of deucrictibant will be poised to be take prophylactic market share if its Phase 3 replicates the impressive Phase 2 data, JMP says.